PDF(Pubmed)
Abstract：
UNASSIGNED: To investigate the efficacy and safety of rituximab (RTX) with or without glucocorticoid (GC) in inducing remission of minimal change disease (MCD) in adults.
UNASSIGNED: Twenty-one adult MCD patients were included in the study. The patients were assigned to the following three groups according to their background before RTX treatment: an RTX single drug direct induction treatment group (Group A; n = 9), a short-term, low-dose GC combined with RTX induction treatment group (Group B; n = 4), and a short-term, adequate-dose GC-induced remission and RTX maintenance treatment group (Group C; n = 8). The primary endpoints were the time to induction of remission and the rate of clinical remission at 12 months.
UNASSIGNED: All patients achieved clinical remission, with 19 (90.48%) achieving complete remission (CR), and the median remission time was 4 (2.5, 12) weeks. Eight (88.89%) patients in Group A achieved CR, and the median remission time was 3 (2.25, 14) weeks. In Group B, three (75.00%) patients achieved CR, with a median remission time of 4 (4, 10) weeks. In Group C, eight (100.00%) patients achieved CR, and the median remission time was 3.5 (2, 4) weeks.
UNASSIGNED: In MCD patients without acute kidney injury, adequate RTX alone or short-term combined treatment with low-dose GCs can effectively induce and maintain MCD remission. Adequate short-term GCs combined with RTX maintenance may be an effective alternative for MCD patients in context of acute kidney injury. There is a need to investigate different induction therapy regimens for the remission of MCD patients with different backgrounds.
UNASSIGNED: Twenty-one adult MCD patients were included in the study. The patients were assigned to the following three groups according to their background before RTX treatment: an RTX single drug direct induction treatment group (Group A; n = 9), a short-term, low-dose GC combined with RTX induction treatment group (Group B; n = 4), and a short-term, adequate-dose GC-induced remission and RTX maintenance treatment group (Group C; n = 8). The primary endpoints were the time to induction of remission and the rate of clinical remission at 12 months.
UNASSIGNED: All patients achieved clinical remission, with 19 (90.48%) achieving complete remission (CR), and the median remission time was 4 (2.5, 12) weeks. Eight (88.89%) patients in Group A achieved CR, and the median remission time was 3 (2.25, 14) weeks. In Group B, three (75.00%) patients achieved CR, with a median remission time of 4 (4, 10) weeks. In Group C, eight (100.00%) patients achieved CR, and the median remission time was 3.5 (2, 4) weeks.
UNASSIGNED: In MCD patients without acute kidney injury, adequate RTX alone or short-term combined treatment with low-dose GCs can effectively induce and maintain MCD remission. Adequate short-term GCs combined with RTX maintenance may be an effective alternative for MCD patients in context of acute kidney injury. There is a need to investigate different induction therapy regimens for the remission of MCD patients with different backgrounds.
摘要：
■研究利妥昔单抗（RTX）联合或不联合糖皮质激素（GC）诱导成人微小病变（MCD）缓解的疗效和安全性。
■21名成年MCD患者纳入研究。根据RTX治疗前的背景将患者分为以下三组：RTX单药直接诱导治疗组（A组；n=9），短期的,低剂量GC联合RTX诱导治疗组（B组；n=4），短期的,足量GC诱导缓解和RTX维持治疗组（C组；n=8）。主要终点是诱导缓解时间和12个月时的临床缓解率。
■所有患者均达到临床缓解，19（90.48%）达到完全缓解（CR），中位缓解时间为4(2.5、12)周。A组8例（88.89%）患者达到CR，中位缓解时间为3(2.25,14)周。B组,3例（75.00%）患者达到CR，中位缓解时间为4（4，10）周。C组,8例（100.00%）患者达到CR，中位缓解时间为3.5(2,4)周。
■在没有急性肾损伤的MCD患者中，适当的RTX单独治疗或与低剂量GC的短期联合治疗可有效诱导和维持MCD缓解。在急性肾损伤的情况下，适当的短期GCs联合RTX维持可能是MCD患者的有效替代方案。有必要研究不同背景的MCD患者缓解的不同诱导治疗方案。
■21名成年MCD患者纳入研究。根据RTX治疗前的背景将患者分为以下三组：RTX单药直接诱导治疗组（A组；n=9），短期的,低剂量GC联合RTX诱导治疗组（B组；n=4），短期的,足量GC诱导缓解和RTX维持治疗组（C组；n=8）。主要终点是诱导缓解时间和12个月时的临床缓解率。
■所有患者均达到临床缓解，19（90.48%）达到完全缓解（CR），中位缓解时间为4(2.5、12)周。A组8例（88.89%）患者达到CR，中位缓解时间为3(2.25,14)周。B组,3例（75.00%）患者达到CR，中位缓解时间为4（4，10）周。C组,8例（100.00%）患者达到CR，中位缓解时间为3.5(2,4)周。
■在没有急性肾损伤的MCD患者中，适当的RTX单独治疗或与低剂量GC的短期联合治疗可有效诱导和维持MCD缓解。在急性肾损伤的情况下，适当的短期GCs联合RTX维持可能是MCD患者的有效替代方案。有必要研究不同背景的MCD患者缓解的不同诱导治疗方案。
